19477
Overview
CAR-T therapies have underperformed in solid tumors because of antigen heterogeneity and a suppressive tumor microenvironment (TME). Our tumor-antigen-agnostic cell therapy locally targets the tumor microenvironment. Anti-TREM2 CAR-T cells eliminate TREM2+ macrophages and locally secrete pro-inflammatory IL-12 by using synthetic regulatory circuits. The local reprogramming of the immune system in the TME enables durable tumor suppression without systemic toxicity.
Applications
- Universal CAR-T cell therapy for solid tumors
- Combination therapy to enhance immune checkpoint inhibitor efficacy
Differentiation
- Tumor-antigen independent targeting
- Broad solid-tumor applicability
- Localized IL-12 release without systemic exposure
- Tumor-restricted activation, driven by local TME signals
Development Stage
- Efficacy validated in mouse models of colorectal cancer and fibrosarcoma showing durable anti-tumor effect
- Safety: no detectable in-vivo systemic IL-12 toxicity
Contact for more information
